![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
CK Chan, F Sannajust and GA Head
Neuropharmacology Laboratory, Baker Medical Research Institute, Prahran, Victoria, Australia.
The present study in conscious rabbits with intracisternal (i.c.) catheters sought to determine the relative contribution of the I1 subtype of imidazoline receptors (IR) and alpha 2 adrenoceptors to the hypotensive effects of rilmenidine, clonidine and moxonidine with an I1- IR/alpha 2 adrenoceptor antagonist efaroxan and a specific alpha 2 adrenoceptor antagonist 2-methoxyidazoxan (2-MI). The alpha 2 adrenoceptor antagonist effect of efaroxan was compared with 2-MI by performing cumulative dose-response curves in the presence of alpha- methyldopa (400 micrograms/kg i.c.). 2-MI was 5.6 times more potent than efaroxan at reversing 75% of the hypotension elicited by alpha- methyldopa (P < .025). This dose ratio was used to match doses of efaroxan and 2-MI for similar alpha 2 adrenoceptor blockade. The effects of efaroxan (4.1, 13, 41 micrograms/kg i.c.) and 2-MI (0.74, 2.3, 7.4 micrograms/kg i.c.) were investigated on a single i.c. dose of rilmenidine (12 micrograms/kg), clonidine (0.75 microgram/kg) and moxonidine (0.51 microgram/kg). These doses of the antihypertensive agents, which were determined from cumulative dose-response curves, produce 90% of the maximum hypotension. Efaroxan was more effective at reversing the hypotension induced by moxonidine and rilmenidine than was 2-MI (P < .01). These findings suggest that rilmenidine and moxonidine act predominantly via IR. By contrast, 2-MI was more effective at reversing the clonidine-induced hypotension than was efaroxan (P < .001), suggesting that clonidine acts mainly via alpha 2 adrenoceptors in conscious normotensive rabbits. Thus, a higher selectivity of the second generation agents moxonidine and rilmenidine for I1-IR over alpha 2 adrenoceptors, compared with the first generation agent clonidine, appears to be necessary for this effect to be manifested in their hypotensive actions.
This article has been cited by other articles:
|
|
 |
|
  K. Kagawa, Y. Hayashi, I. Itoh, M. Iwasaki, K. Takada, T. Kamibayashi, A. Yamatodani, and T. Mashimo Identification of the Central Imidazoline Receptor Subtype Involved in Modulation of Halothane-Epinephrine Arrhythmias in Rats Anesth. Analg., December 1, 2005; 101(6): 1689 - 1694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. El-Mas and A. A. Abdel-Rahman Differential modulation by estrogen of {alpha}2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats J Appl Physiol, October 1, 2004; 97(4): 1237 - 1244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yamazato, A. Sakima, J. Nakazato, S. Sesoko, H. Muratani, and K. Fukiyama Hypotensive and sedative effects of clonidine injected into the rostral ventrolateral medulla of conscious rats Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2001; 281(6): R1868 - R1876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Poisson, M.-O. Christen, and F. Sannajust Protective Effects of I1-Antihypertensive Agent Moxonidine against Neurogenic Cardiac Arrhythmias in Halothane-Anesthetized Rabbits J. Pharmacol. Exp. Ther., June 1, 2000; 293(3): 929 - 938. [Abstract] [Full Text]
|
|
|
|
|
|
M. M. El-Mas and A. A. Abdel-Rahman Ethanol Counteraction of I1-Imidazoline but Not Alpha-2 Adrenergic Receptor-Mediated Reduction in Vascular Resistance in Conscious Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 455 - 462. [Abstract] [Full Text]
|
|
|
|
|
|
D. J. Reis and J. E. Piletz The imidazoline receptor in control of blood pressure by clonidine and allied drugs Am J Physiol Regulatory Integrative Comp Physiol, November 1, 1997; 273(5): R1569 - R1571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ernsberger and M. A. Haxhiu The I1-imidazoline-binding site is a functional receptor mediating vasodepression via the ventral medulla Am J Physiol Regulatory Integrative Comp Physiol, November 1, 1997; 273(5): R1572 - R1579. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
